Pterostilbene-Mediated Inhibition of Cell Proliferation and Cell Death Induction in Amelanotic and Melanotic Melanoma

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Melanoma is a rapidly increasing cancer globally, with advanced stages posing significant treatment challenges.
• There is a critical need for novel therapeutic agents to combat melanoma.
• Pterostilbene, a naturally occurring stilbene, exhibits various pharmacological properties.

Purpose of the Study:

• To investigate the effects of pterostilbene on the proliferation and apoptosis of human melanoma cell lines.
• To evaluate pterostilbene's impact on cell cycle progression and key molecular markers associated with apoptosis.

Main Methods:

• Cell proliferation was assessed using the Bromodeoxyuridine (BRDU) assay.
• Apoptosis and cell cycle distribution were analyzed via flow cytometry.
• Gene expression (BAX, CASP9) and protein levels (p21, caspase 3 activity) were quantified using real-time RT-qPCR and ELISA.

Main Results:

• Pterostilbene significantly reduced the proliferation of both amelanotic (C32) and melanotic (A2058) melanoma cells.
• In amelanotic C32 cells, pterostilbene induced apoptosis, evidenced by increased BAX and CASP9 gene expression, caspase 3 activation, and DNA fragmentation.
• Pterostilbene did not significantly impact apoptosis in the melanotic A2058 cell line.

Conclusions:

• Pterostilbene demonstrates anticancer potential against human melanoma cells, particularly amelanotic types.
• Further research is warranted to fully understand pterostilbene's mechanisms and therapeutic efficacy in different melanoma subtypes.